Compound Planning Inc. Sells 1,913 Shares of Axon Enterprise, Inc $AXON

Compound Planning Inc. trimmed its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 60.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,235 shares of the biotechnology company’s stock after selling 1,913 shares during the period. Compound Planning Inc.’s holdings in Axon Enterprise were worth $524,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Darwin Wealth Management LLC acquired a new position in shares of Axon Enterprise in the 2nd quarter valued at approximately $37,000. Creative Financial Designs Inc. ADV acquired a new stake in shares of Axon Enterprise during the 4th quarter worth approximately $28,000. Sound Income Strategies LLC increased its stake in Axon Enterprise by 550.0% in the fourth quarter. Sound Income Strategies LLC now owns 52 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 44 shares during the last quarter. Camelot Portfolios LLC bought a new position in Axon Enterprise in the fourth quarter valued at approximately $30,000. Finally, AlphaCentric Advisors LLC acquired a new position in Axon Enterprise during the fourth quarter valued at approximately $34,000. 79.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Caitlin Elizabeth Kalinowski sold 564 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $478.97, for a total transaction of $270,139.08. Following the completion of the transaction, the director directly owned 3,632 shares of the company’s stock, valued at $1,739,619.04. This trade represents a 13.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of Axon Enterprise stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $485.00, for a total value of $753,690.00. Following the transaction, the insider directly owned 34,024 shares in the company, valued at $16,501,640. The trade was a 4.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 58,989 shares of company stock valued at $30,527,983 over the last quarter. 4.20% of the stock is currently owned by company insiders.

Axon Enterprise Stock Up 4.2%

Shares of NASDAQ AXON opened at $547.65 on Wednesday. The company has a 50 day simple moving average of $488.89 and a 200 day simple moving average of $477.58. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93. Axon Enterprise, Inc has a 1 year low of $339.01 and a 1 year high of $885.91. The firm has a market cap of $44.14 billion, a PE ratio of 219.94, a price-to-earnings-growth ratio of 10.72 and a beta of 1.38.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm had revenue of $807.35 million for the quarter, compared to analyst estimates of $778.90 million. During the same period in the previous year, the firm posted $1.47 EPS. The company’s revenue for the quarter was up 33.7% compared to the same quarter last year. On average, research analysts forecast that Axon Enterprise, Inc will post 1.63 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on AXON. Barclays cut their target price on Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. TD Cowen reiterated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, July 22nd. Piper Sandler boosted their price target on Axon Enterprise from $674.00 to $724.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Citizens Jmp restated a “market outperform” rating and set a $700.00 price objective on shares of Axon Enterprise in a research report on Thursday, June 25th. Finally, Morgan Stanley set a $600.00 price objective on Axon Enterprise in a research note on Thursday, May 7th. Fifteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and a consensus target price of $725.25.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.